Overview
Albendazole and Mebendazole are both benzimidazole anthelmintics widely used for treating intestinal parasitic infections. While they share the same mechanism of action, they differ significantly in bioavailability, spectrum of activity, approved indications, and pharmacokinetics. Understanding these differences is critical for pharmaceutical manufacturers targeting global markets.
Global Prevalence: Soil-transmitted helminth infections affect over 1.5 billion people worldwide, primarily in tropical and subtropical regions. Both Albendazole and Mebendazole are on the WHO Model List of Essential Medicines.
Chemical Profile Comparison
| Property | Albendazole | Mebendazole |
|---|---|---|
| CAS Number | 54965-21-8 | 31431-39-7 |
| Molecular Formula | C₁₂H₁₅N₃O₂S | C₁₆H₁₃N₃O₃ |
| Molecular Weight | 265.33 g/mol | 295.29 g/mol |
| Appearance | White to off-white powder | White to slightly yellow powder |
| Solubility | Practically insoluble in water | Practically insoluble in water |
| Purity (API grade) | ≥99.0% | ≥99.0% |
Key Differences
Albendazole
- Better oral bioavailability (when taken with fatty food)
- Systemic absorption — treats tissue parasites
- Broader spectrum (cysticercosis, echinococcosis)
- Single dose for many indications
- WHO Essential Medicine (intestinal helminths)
- Used in mass drug administration programs
Mebendazole
- Poor systemic absorption (<1%)
- Acts mainly in GI tract
- Limited to intestinal worm infections
- Chewable tablet form common
- WHO Essential Medicine
- Well-established safety profile
Indications Comparison
| Indication | Albendazole | Mebendazole |
|---|---|---|
| Ascariasis (roundworm) | ✅ Yes | ✅ Yes |
| Hookworm | ✅ Yes | ✅ Yes |
| Trichuriasis (whipworm) | ✅ Yes | ✅ Yes |
| Enterobiasis (pinworm) | ✅ Yes | ✅ Yes |
| Neurocysticercosis | ✅ Yes | ❌ No |
| Echinococcosis | ✅ Yes | ❌ Limited |
| Giardiasis | ✅ Yes (off-label) | ❌ No |
| Lymphatic filariasis | ✅ Yes | ❌ No |
Which API to Choose?
Choose Albendazole if you need broader coverage including systemic parasitic infections. It is the preferred choice for WHO mass drug administration programs and markets requiring broader spectrum activity.
Choose Mebendazole if your target market focuses on common intestinal helminths with a proven, ultra-safe profile. It's particularly suitable for pediatric chewable formulations due to minimal systemic exposure.
Request Antiparasitic API Quotation
We supply both Albendazole and Mebendazole with GMP certificate, COA, and full documentation